GPT, Rosalind, and Generic Drugs: What OpenAI’s Life-Sciences Model Actually Changes
The life-sciences industry has a new kind of bottleneck—and it’s not the science. It’s the workflow.
For years, the promise of AI in drug discovery has been framed as …

🚨 The drug patent cliff just got a new kind of pressure test.
OpenAI’s GPT—paired with Rosalind’s scientific workflow—has reportedly been used to “smash” some of the most stubborn drug patent cliffs, with claims of ~70% faster development cycles f…

Predict the Attack: How to Forecast Paragraph IV Filings and Neutralize “Skinny Label” Threats
In pharma, the most expensive surprises rarely arrive with a press release. They arrive quietly—months before launch—inside the legal and regulatory machiner…

Your drug’s “patent life” isn’t one number in the GCC. It’s a moving target. Here’s how to know exactly what you’re really buying.
If you’re a brand team, investor, or in-house counsel working on the Gulf Cooperation Council (GCC), you already know the…

Biopharma teams don’t lose deals because they lack ambition—they lose because they mis-time the pitch.
In licensing, partnerships, and BD strategy, timing is everything. But too often, the “when” is treated like a calendar exercise rather than a commer…